TransMedics Group, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
TransMedics Group (TMDX) and SoFi Technologies (SOFI) have seen significant stock declines. TMDX's revenue grew 21% YoY to $189.9M, but profits fell 52%. SOFI's revenue rose 43% to $1.2B, with net income up 61%. Both face near-term challenges but are seen as long-term opportunities.
Weill David purchased 1,336 shares of TransMedics Group, Inc. (TMDX) at $81.63 ($0.11M total) on 2026-09-11.
TransMedics (TMDX) named Fernando Araujo as CFO, effective September 21, 2026. Araujo has 20+ years of finance experience in healthcare, industrial, and energy sectors. The company reiterated its 2026 revenue guidance of $737M-$757M, a 22-25% YoY growth. Araujo will support TransMedics' global growth, while Gerardo Hernandez transitions to a strategic advisory role for Latin America expansion.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TMDX (TransMedics Group, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent TMDX coverage spans earnings, financial news and insider activity.
In the last 30 days, TMDX insiders filed 1 SEC Form 4 transaction — 1 purchase ($109K) and no sales. The most active reporter was Weill David with 1 filing.
Earnings miss on EPS may pressure the stock despite revenue growth.
Small insider purchase by a director may signal confidence but limited material impact.
Executive change may improve financial execution; guidance reaffirmation supports current valuation.
New CFO appointment and reaffirmed guidance may support stock stability and potential upside as the company executes growth plans.
Earnings quality concern (sharp adjusted net income decline) is the immediate driver, despite raised 2026 sales guidance and continued reinvestment.
AlphAI scores every news story that mentions TMDX with an AI model for sentiment and relevance, and aggregates insider trades from TransMedics Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TransMedics Group (TMDX) and SoFi Technologies (SOFI) have seen significant stock declines. TMDX's revenue grew 21% YoY to $189.9M, but profits fell 52%. SOFI's revenue rose 43% to $1.2B, with net income up 61%. Both face near-term challenges but are seen as long-term opportunities.
3 min readWeill David purchased 1,336 shares of TransMedics Group, Inc. (TMDX) at $81.63 ($0.11M total) on 2026-09-11.
1 min readTransMedics (TMDX) named Fernando Araujo as CFO, effective September 21, 2026. Araujo has 20+ years of finance experience in healthcare, industrial, and energy sectors. The company reiterated its 2026 revenue guidance of $737M-$757M, a 22-25% YoY growth. Araujo will support TransMedics' global growth, while Gerardo Hernandez transitions to a strategic advisory role for Latin America expansion.
2 min readTransMedics Group, Inc. (TMDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook Andover, Mass. – September 10, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for trans
2 min readTransMedics (NASDAQ: TMDX) shares fell about 8% after its Q2 results. The company reported 21% sales growth, but adjusted net income dropped from $35M in Q2 last year to $16M this year, below expectations. Management said about $19M of the change reflected spending on a next-gen kidney OCS, clinical programs, and a manufacturing plant in Italy.
4 min readTransMedics Group (Nasdaq: TMDX) reported Q2 2026 revenue of $189.9 million, up 21% year over year, with product revenue $111.2 million and service revenue $78.8 million. Net income was $14.7 million, or $0.41 per diluted share. The company raised full-year 2026 revenue guidance (excluding PAD Aviation) to $737 million to $757 million.
6 min readTransMedics Group, Inc. (TMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TransMedics Reports Second Quarter 2026 Financial Results Andover, Mass. – August 4, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and
4 min readTransMedics (Nasdaq: TMDX) said it granted inducement equity awards on July 29, 2026 to nine new employees under Nasdaq Rule 5635(c)(4). It issued non-qualified stock options for 18,762 shares (10-year term, $78.00 exercise price) and 12,414 restricted stock units. Options vest 25% after one year, then monthly over three years; RSUs vest 25% each of four anniversaries.
2 min readTransMedics Group, Inc. (Nasdaq: TMDX) said it granted non-qualified stock options for 18,762 shares and 12,414 restricted stock units to nine employees on July 29, 2026 as inducement awards under Nasdaq Listing Rule 5635(c)(4). Options exercise price was $78.00, the July 29 closing price, with 10-year terms.
2 min readTheFly reported July 6 that Evercore ISI cut its TransMedics Group (TMDX) price target to $90 from $100 while keeping an Outperform rating, citing generally stable procedure volumes and capital spending trends. On the same day, TMDX said it will invest in PAD Aviation to expand its Organ Care System OCS program into Europe, aiming to improve organ access and transplant logistics.
4 min read
